title: [Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].
abstract: The best therapeutic effect in the treatment of patients with chronic virus hepatitis C was observed with the use of cycloferon included into the standard antiviral therapy with alpha-interferon and ribavirine. The 18-month observation revealed an increase of the biochemical and antiviral responses to 41.0 and 30.7% respectively. The use of cycloferon provided a decrease in the frequency and manifestation of the side effects. The therapy with the use of cycloferon had a favourable effect on the indices of the quality of life of the patients: by the majority of the scales of the questionnaires it was appraised maximum (from 85 to 96 points).
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: S N
authors.initials: SN
authors.lastname: Kovalenko
authors.forename: T V
authors.initials: TV
authors.lastname: Sologub
authors.forename: O V
authors.initials: OV
authors.lastname: Anikina
mesh_terms: D000166:Acridines / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007369:Interferon Inducers / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011788:Quality of Life; D012254:Ribavirin / Q000008:administration & dosage*; D011795:Surveys and Questionnaires
chemical_list: D000166:Acridines; D000998:Antiviral Agents; D007369:Interferon Inducers; D016898:Interferon-alpha; D012254:Ribavirin; C026430:10-carboxymethyl-9-acridanone